<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Metformin for treatment of the polycystic ovary syndrome
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Metformin for treatment of the polycystic ovary syndrome
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Metformin for treatment of the polycystic ovary syndrome
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert L Barbieri, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David A Ehrmann, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Peter J Snyder, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            William F Crowley, Jr, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kathryn A Martin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 01, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The polycystic ovary syndrome (PCOS) is characterized by both oligo/amenorrhea and androgen excess in women. When fully expressed, the manifestations include irregular menstrual cycles, hirsutism, obesity, and a constellation of cardiometabolic disturbances. It is a common endocrinopathy, occurring in 5 to 7 percent of reproductive age women [
         <a href="#rid1">
          1-3
         </a>
         ].
        </p>
        <p>
         The use of
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         in the management of PCOS will be reviewed here. The clinical manifestations, diagnosis, and other treatment options for PCOS are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/7436.html" rel="external">
          "Clinical manifestations of polycystic ovary syndrome in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7385.html" rel="external">
          "Diagnosis of polycystic ovary syndrome in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7421.html" rel="external">
          "Treatment of polycystic ovary syndrome in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          OVERVIEW
         </span>
         <span class="headingEndMark">
          —
         </span>
         Interest in the use of
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         , an insulin-lowering drug, in PCOS increased when it was appreciated that insulin resistance played an important role in the pathophysiology of the disorder. However, we no longer recommend the use of metformin as a first-line therapy for any indication in women with PCOS. Metformin is typically the first-line treatment for patients with type 2 diabetes; it is not approved for use in prediabetes or PCOS, although it is often prescribed for treatment of these conditions.
        </p>
        <p>
         Early trials in women with PCOS subsequently demonstrated a small benefit for weight reduction, a decrease in serum androgens (without improvement in hirsutism), and restoration of menstrual cycles in approximately 50 percent of women with oligomenorrhea (although not always ovulatory). Early data also suggested that
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         was effective for ovulation induction in anovulatory women with PCOS. As a result, metformin was used "off-label" for a number of these indications [
         <a href="#rid4">
          4,5
         </a>
         ].
        </p>
        <p>
         However, available data do not support the use of
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         for treatment of hirsutism or as first-line treatment for ovulation induction in this population. However, there may be clinical situations where metformin might be used as an alternative to other first-line treatments for hirsutism (combined estrogen-progestin oral contraceptives [COCs] and antiandrogens or ovulation induction [
         <a class="drug drug_general" data-topicid="10064" href="/z/d/drug information/10064.html" rel="external">
          letrozole
         </a>
         or
         <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">
          clomiphene
         </a>
         ]) when there is a contraindication to those agents or the patient prefers not to use a first-line agent.
        </p>
        <p class="headingAnchor" id="H599677501">
         <span class="h2">
          Mechanisms of action
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          Metformin
         </a>
         's major effect is to decrease hepatic glucose production, thus reducing the need for insulin secretion; it also decreases intestinal absorption of glucose. Metformin also has an antilipolytic effect that lowers free fatty acid concentrations, thus reducing gluconeogenesis [
         <a href="#rid6">
          6,7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Pharmacology
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          Metformin
         </a>
         is a biguanide antihyperglycemic approved for management of type 2 diabetes mellitus when hyperglycemia cannot be managed by diet and exercise alone. Unlike sulfonylureas, it does not produce hypoglycemia in either normal subjects or patients with type 2 diabetes. Metformin is also suggested for diabetes prevention in patients age &lt;60 years and/or body mass index (BMI) ≥35 kg/m
         <sup>
          2
         </sup>
         , women with a history of gestational diabetes mellitus (GDM) with impaired fasting glucose (IFG), impaired glucose tolerance (IGT), or glycated hemoglobin (A1C) of 5.7 to 6.4 percent, in whom lifestyle interventions failed to improve glycemic indices. (See
         <a class="medical medical_review" href="/z/d/html/1809.html" rel="external">
          "Metformin in the treatment of adults with type 2 diabetes mellitus"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1774.html" rel="external">
          "Prevention of type 2 diabetes mellitus", section on 'Metformin'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          Metformin
         </a>
         is rapidly absorbed from the small intestine with peak plasma levels occurring two hours after ingestion. Food decreases the rate of drug absorption and peak drug concentration, although taking the medication with food is recommended to attenuate its gastrointestinal side effects. Metformin is not metabolized and is largely excreted in the urine. Renal clearance is approximately 3.5 times greater than renal clearance of creatinine, which indicates that tubular secretion is the main route of excretion. The plasma elimination half-life is approximately six hours.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Dose
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          Metformin
         </a>
         is available in a generic form as 500, 850, and 1000 mg tablets. The target dose is 1500 to 2000 mg daily; clinically significant responses are not regularly observed at doses less than 1000 mg daily. Many clinicians begin treatment with 500 mg taken with a meal to reduce gastrointestinal side effects. If tolerated, the dose can be increased to 500 mg at both lunch and dinner and then to 500 mg at breakfast, lunch, and dinner. One to two weeks should elapse between increases in dose.
        </p>
        <p>
         Extended-release tablets are available in a generic form as 500, 750, and 1000 mg tablets. Extended-release
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         may be associated with fewer side effects, and in general, we suggest starting with these formulations rather than the short-acting ones. With extended-release tablets, the entire daily dose may be given at dinner time. The dose is initially 500 mg with dinner and is escalated gradually to a maximum of 2000 to 2250 mg.
        </p>
        <p>
         Finally,
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         exists in both a liquid formulation (500 mg/5 mL) and a specially formulated tablet designed to release the medication more slowly into the intestinal tract [
         <a href="#rid8">
          8
         </a>
         ]. In instances where the traditional formulations are not tolerated, it is occasionally helpful to have the patient try either the liquid or slow-release formulation before abandoning metformin therapy.
        </p>
        <p class="headingAnchor" id="H199669185">
         <span class="h2">
          Side effects and precautions
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common side effects are gastrointestinal: diarrhea, nausea or vomiting, flatulence, indigestion, and abdominal discomfort. These symptoms are usually mild, transient, and reversible after dose reduction or discontinuation of the drug.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          Metformin
         </a>
         also reduces intestinal absorption of vitamin B12 in up to 30 percent of patients and lowers serum vitamin B12 concentrations in 5 to 10 percent but only rarely causes megaloblastic anemia [
         <a href="#rid9">
          9
         </a>
         ]. In women with PCOS taking metformin, we suggest yearly monitoring for B12 deficiency with a complete blood count (CBC) and serum B12 concentration. In addition, women should make sure they meet the recommended dietary allowances for B12 (2.6 mcg for adults). This can be done either with food or supplements. (See
         <a class="medical medical_review" href="/z/d/html/1809.html" rel="external">
          "Metformin in the treatment of adults with type 2 diabetes mellitus", section on 'Vitamin B12 deficiency'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7155.html" rel="external">
          "Clinical manifestations and diagnosis of vitamin B12 and folate deficiency"
         </a>
         .)
        </p>
        <p>
         Lactic acidosis has been described, but it is an extremely rare complication in otherwise healthy individuals. However,
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         should not be prescribed for women with other conditions that increase the risk of lactic acidosis, such as renal insufficiency, congestive heart failure, or sepsis. (See
         <a class="medical medical_review" href="/z/d/html/1809.html" rel="external">
          "Metformin in the treatment of adults with type 2 diabetes mellitus", section on 'Lactic acidosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H199669091">
         <span class="h3">
          Breastfeeding
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although data are limited,
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         use by breastfeeding women with PCOS does not appear to be associated with adverse outcomes. Concentrations of metformin in breast milk appear to be low, and the mean infant exposure to metformin has been reported to be well below the level of concern for breastfeeding; no adverse effects on blood glucose of nursing infants have been reported [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          POTENTIAL USES
         </span>
         <span class="headingEndMark">
          —
         </span>
         As discussed above, treatment of type 2 diabetes mellitus is the only approved indication for
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         . Nevertheless, it has been used "off-label" to treat or prevent several clinical problems associated with PCOS, including oligomenorrhea, hirsutism, anovulatory infertility, prevention of pregnancy complications, and obesity [
         <a href="#rid4">
          4,11
         </a>
         ]. However, it is not a first-line drug for oligomenorrhea, and it is ineffective for most other indications. (See
         <a class="local">
          'No longer indicated'
         </a>
         below.)
        </p>
        <p>
         Although it might be preferable to treat only insulin-resistant women with PCOS, there is currently no readily available, reliable test to evaluate the presence of insulin resistance. Some clinicians do not test at all; others perform an oral glucose tolerance test to look for impaired glucose tolerance (IGT) and check for elevated insulin levels. We do not suggest measuring insulin levels, as the results do not affect management. (See
         <a class="medical medical_review" href="/z/d/html/1762.html" rel="external">
          "Insulin resistance: Definition and clinical spectrum"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7385.html" rel="external">
          "Diagnosis of polycystic ovary syndrome in adults", section on 'Cardiometabolic risk assessment'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H328336713">
         <span class="h2">
          Reproductive
         </span>
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h3">
          Oligomenorrhea
         </span>
         <span class="headingEndMark">
          —
         </span>
         For women with oligomenorrhea due to PCOS who need endometrial protection (and contraception or management of hirsutism), we suggest combined estrogen-progestin oral contraceptives (COCs) as first-line therapy. Therapeutic effects include the following (see
         <a class="medical medical_review" href="/z/d/html/7421.html" rel="external">
          "Treatment of polycystic ovary syndrome in adults", section on 'Menstrual dysfunction'
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A decrease in luteinizing hormone (LH) secretion and a resulting decrease in ovarian androgen production
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An increase in hepatic production of sex hormone-binding globulin (SHBG) with a decrease in bioavailable testosterone
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A decrease in adrenal androgen secretion
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Regular withdrawal bleeding
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prevention of endometrial hyperplasia
        </p>
        <p>
        </p>
        <p>
         For second-line therapy and for situations where COCs are contraindicated, we suggest continuous or cyclic progestin-only treatment, or a levonorgestrel-releasing intrauterine device (IUD) for endometrial protection. (See
         <a class="medical medical_review" href="/z/d/html/5461.html" rel="external">
          "Contraception: Progestin-only pills (POPs)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/116579.html" rel="external">
          "Intrauterine contraception: Background and device types", section on 'Levonorgestrel IUD'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          Metformin
         </a>
         may also be used as second-line therapy (particularly in women with contraindications to COC use), but it has not been proven to be endometrial protective.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          Metformin
         </a>
         will restore ovulatory menses in approximately 50 percent of women with PCOS [
         <a href="#rid12">
          12-14
         </a>
         ], although some studies report ovulatory rates from 23 to 90 percent [
         <a href="#rid15">
          15-21
         </a>
         ]. Evidence for the efficacy of metformin includes the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one trial, 23 women with PCOS were randomly assigned to receive
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         (500 mg three times per day) or placebo for six months [
         <a href="#rid12">
          12
         </a>
         ]. Approximately one-half of the women treated with metformin achieved normalization of menstrual function, confirmed by intermenstrual interval and luteal phase serum progesterone monitoring.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a meta-analysis of 13 trials, women treated with
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         had a fourfold higher chance of ovulating than women treated with placebo [
         <a href="#rid22">
          22
         </a>
         ]. A similar fourfold increase was seen for the combination of metformin plus
         <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">
          clomiphene
         </a>
         when compared with clomiphene alone. The use of metformin for ovulation induction is reviewed below. (See
         <a class="local">
          'Anovulatory infertility'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Endometrial protection
         </strong>
         – Some women do not ovulate during the first six months of treatment, and therefore, we recommend cyclic progestin treatment during this interval. Although some women may have restoration of menses with
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         , unless cycles are regular and ovulatory, one cannot assume that the patient has reliable endometrial protection. For those who have menses that are irregular and anovulatory, cyclic progestins or COCs are necessary. We typically use either micronized progesterone (200 mg/day for 14 days every one to two months) or
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          medroxyprogesterone acetate
         </a>
         (10 mg/day for 12 to 14 days every one to two months).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Women who do not attain regular ovulatory menses should be treated with cyclic progestin therapy to reduce the risk of endometrial hyperplasia until regular menses are established. (See
         <a class="medical medical_review" href="/z/d/html/3217.html" rel="external">
          "Endometrial hyperplasia: Clinical features, diagnosis, and differential diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         During the initial phase of oligomenorrhea, it may be difficult to determine if ovulation has taken place. Measuring serum progesterone every 10 days may be one approach, although cumbersome, to identify if ovulation has occurred following initiation of
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We do not typically use this approach. If menstrual cycles are regular, we do not check serum progesterone levels. If cycles are irregular, we add cyclic progestin therapy as outlined above. If the patient then develops regular menses between courses of cyclic progestin therapy, the progestin can be stopped to see if spontaneous ovulations have developed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A contraceptive (eg, diaphragm, condom) should be prescribed for all sexually active women not planning pregnancy since
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         treatment may induce ovulation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          COCs versus
         </strong>
         <strong>
          metformin
         </strong>
         – There have been concerns that estrogen-progestin contraceptives may worsen insulin resistance in women with PCOS and that
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         should therefore be the preferred treatment. However, while COCs are less beneficial than metformin for insulin sensitivity, they are more effective for androgen suppression and menstrual cycle control. In addition, available data have not shown any evidence of adverse metabolic risk [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a meta-analysis of four trials that included 104 women with PCOS,
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         was less effective than COCs for improving menstrual pattern and in reducing serum total testosterone concentration but more effective for reducing fasting insulin and not increasing fasting triglyceride concentrations [
         <a href="#rid24">
          24
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7421.html" rel="external">
          "Treatment of polycystic ovary syndrome in adults", section on 'Metabolic effects of COCs in PCOS'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing
         </strong>
         – The optimum dose of
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         to restore ovulatory menses has not been determined. The two best studied metformin regimens are 500 mg three times daily (1500 mg daily) and 850 mg twice daily (1700 mg daily). Some clinicians go up to 2000 mg daily [
         <a href="#rid25">
          25
         </a>
         ]. Extended-release preparations can also be used (500 mg tablets, with the entire dose of 1500 to 2000 mg administered with dinner).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2987655991">
         <span class="h3">
          IVF pretreatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         In women with PCOS, the administration of
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         before or during in vitro fertilization (IVF) cycles does not appear to improve clinical pregnancy or live-birth rates [
         <a href="#rid26">
          26,27
         </a>
         ]. However, metformin administration before or during IVF cycles does appear to reduce the number of retrieved oocytes [
         <a href="#rid28">
          28
         </a>
         ] and the risk of ovarian hyperstimulation syndrome (OHSS) [
         <a href="#rid26">
          26,27,29
         </a>
         ]. Similar estimates of benefits were reported in two meta-analyses (odds ratio [OR] 0.27 for risk of OHSS with metformin compared with placebo use). Although metformin therapy is a potential option to lower the risk of OHSS with IVF, there appear to be more effective strategies, such as gonadotropin-releasing hormone (GnRH) antagonists [
         <a href="#rid30">
          30
         </a>
         ]. The addition of metformin in this setting does not appear to lower the risk of multiple gestation [
         <a href="#rid31">
          31
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7412.html" rel="external">
          "Prevention of ovarian hyperstimulation syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3445176806">
         <span class="h2">
          Metabolic
         </span>
         <span class="headingEndMark">
          —
         </span>
         In a trial described above [
         <a href="#rid12">
          12
         </a>
         ], compared with placebo, the
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         group had improvement in plasma insulin and insulin sensitivity (as measured by glucose clamp studies), a reduction in serum free testosterone, and an increase in mean serum high-density lipoprotein (HDL) cholesterol. Both the biochemical and clinical changes were independent of changes in body weight and were sustained in a follow-up, open, long-term, observational study (mean duration of treatment was 11 months). However, there was no significant reduction in hirsutism, despite the lower free serum testosterone concentration. (See
         <a class="local">
          'Hirsutism'
         </a>
         below.)
        </p>
        <p>
         A second 14-week trial in 94 women with PCOS randomly assigned to
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         or placebo showed similar clinical and metabolic benefits, except in the most obese women (body mass index [BMI] &gt;37 kg/m
         <sup>
          2
         </sup>
         ) [
         <a href="#rid15">
          15
         </a>
         ]. A meta-analysis of 13 trials reported that metformin is associated with a reduction in blood pressure, low-density lipoprotein (LDL), and fasting insulin levels, when compared with placebo [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H599677550">
         <span class="h3">
          Prevention of diabetes mellitus
         </span>
         <span class="headingEndMark">
          —
         </span>
         Women with PCOS are at increased risk for developing type 2 diabetes mellitus or IGT. In a study of 122 obese women with PCOS, 45 percent had either IGT (35 percent) or type 2 diabetes mellitus (10 percent) by age 40 [
         <a href="#rid33">
          33
         </a>
         ]. As is the case in non-PCOS populations, the risk of type 2 diabetes in PCOS appears to be highest among those who are obese and/or have a significant family history of type 2 diabetes [
         <a href="#rid33">
          33
         </a>
         ]. The frequency of diagnosis of type 2 diabetes in women with PCOS varies with the screening test used. A fasting blood glucose may underestimate the prevalence of diabetes when compared with an oral glucose tolerance test. (See
         <a class="medical medical_review" href="/z/d/html/7436.html" rel="external">
          "Clinical manifestations of polycystic ovary syndrome in adults", section on 'IGT/type 2 diabetes'
         </a>
         .)
        </p>
        <p>
         Retrospective data in women with PCOS suggest that
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         therapy may delay or prevent conversion to IGT and diabetes [
         <a href="#rid34">
          34
         </a>
         ]. However, in the absence of clinical trial data, we do not recommend metformin for women with normal glucose tolerance for this indication.
        </p>
        <p class="headingAnchor" id="H599678026">
         <span class="h1">
          NO LONGER INDICATED
         </span>
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Hirsutism
         </span>
         <span class="headingEndMark">
          —
         </span>
         The first-line therapy for treatment of hirsutism caused by PCOS is a combined estrogen-progestin oral contraceptive (COC), as recommended by the 2018 Endocrine Society Guidelines. An antiandrogen is then added after six months if the cosmetic response is suboptimal. (See
         <a class="medical medical_review" href="/z/d/html/7444.html" rel="external">
          "Management of hirsutism in premenopausal women"
         </a>
         .)
        </p>
        <p>
         A number of clinical trials have examined the effects of insulin-lowering agents on circulating androgen concentrations in women with PCOS and have noted a reduction in these hormones with therapy [
         <a href="#rid12">
          12,35-41
         </a>
         ]. Although
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         may reduce serum androgen concentrations, it has limited benefit for the treatment of hirsutism [
         <a href="#rid23">
          23,42-48
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Anovulatory infertility
         </span>
         <span class="headingEndMark">
          —
         </span>
         A structured approach, starting with low-cost interventions and advancing to high-resource interventions, is warranted for treatment of anovulatory infertility in women with PCOS  (
         <a class="graphic graphic_table graphicRef56718" href="/z/d/graphic/56718.html" rel="external">
          table 1
         </a>
         ). The first two management steps are weight loss through caloric restriction and increased exercise for women with a body mass index (BMI) &gt;27 kg/m
         <sup>
          2
         </sup>
         , followed by medical therapy. (See
         <a class="medical medical_review" href="/z/d/html/7421.html" rel="external">
          "Treatment of polycystic ovary syndrome in adults", section on 'Weight loss'
         </a>
         .)
        </p>
        <p>
         First-line options for ovulation induction in anovulatory women with PCOS include
         <a class="drug drug_general" data-topicid="10064" href="/z/d/drug information/10064.html" rel="external">
          letrozole
         </a>
         and
         <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">
          clomiphene
         </a>
         . The best available evidence suggests that letrozole and clomiphene are more effective than
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         for live-birth rates, the most important outcome. Early ovulation induction trials suggested better results with metformin alone or metformin plus clomiphene when compared with clomiphene alone [
         <a href="#rid12">
          12,13,15-19,32,36,49-53
         </a>
         ].
        </p>
        <p>
         However, data from a number of multicenter trials have now reported that while
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         may be effective for restoring ovulation, it appears to be less effective for fertility (live-birth rates) when compared with
         <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">
          clomiphene
         </a>
         [
         <a href="#rid54">
          54-60
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="10064" href="/z/d/drug information/10064.html" rel="external">
          Letrozole
         </a>
         , an aromatase inhibitor, is also effective for ovulation induction in women with PCOS (although it is not approved for this indication). Available data suggest that live-birth rates are higher with letrozole than
         <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">
          clomiphene
         </a>
         , and many experts now suggest letrozole as first-line therapy for anovulatory women with PCOS. (See
         <a class="medical medical_review" href="/z/d/html/7425.html" rel="external">
          "Ovulation induction with letrozole"
         </a>
         .)
        </p>
        <p>
         In a 2012 meta-analysis of 38
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         trials in 3495 women, there was no evidence that metformin improved live-birth rates, whether it was used alone (pooled odds ratio [OR] 1.80, 95% CI 0.52-6.16, three trials, 115 women) or in combination with
         <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">
          clomiphene
         </a>
         (pooled OR 1.16, 95% CI 0.85-1.56, seven trials, 907 women) [
         <a href="#rid22">
          22
         </a>
         ]. Thus, larger trials and a meta-analysis suggest that clomiphene is more effective than metformin for live-birth rates, the most relevant outcome [
         <a href="#rid54">
          54
         </a>
         ], and that the addition of metformin to clomiphene does not provide additional benefit [
         <a href="#rid54">
          54,55
         </a>
         ]. However, in one of the trials, multiple pregnancy rates were higher with clomiphene [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
         A consensus group has recommended against the routine use of
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         for ovulation induction except in women with glucose intolerance [
         <a href="#rid61">
          61
         </a>
         ]. In addition, the American Society for Reproductive Medicine (ASRM) has published a summary of the available evidence on the role of metformin for ovulation induction with PCOS [
         <a href="#rid31">
          31
         </a>
         ]. Although metformin was widely used in the past for women with PCOS for ovulation induction and prevention of miscarriage, multiple gestations, and pregnancy complications, the ASRM concludes that there is insufficient evidence to recommend metformin for any of these indications. Metformin does increase ovulatory rates and pregnancy rates, but unlike
         <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">
          clomiphene
         </a>
         and
         <a class="drug drug_general" data-topicid="10064" href="/z/d/drug information/10064.html" rel="external">
          letrozole
         </a>
         , it does not improve live birth rates and is therefore not the drug of choice. (See
         <a class="medical medical_review" href="/z/d/html/7421.html" rel="external">
          "Treatment of polycystic ovary syndrome in adults", section on 'Ovulation induction medications'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h2">
          Prevention of pregnancy complications
         </span>
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h3">
          Spontaneous abortion
         </span>
         <span class="headingEndMark">
          —
         </span>
         Small observational studies had shown benefits of
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         therapy for reducing the risk of early miscarriage in pregnant women with PCOS, but randomized trials have shown no benefit.
        </p>
        <p>
         The spontaneous abortion rate in women with PCOS is 20 to 40 percent higher than the baseline in the general obstetric population [
         <a href="#rid62">
          62
         </a>
         ]. Three early studies in women with PCOS reported miscarriage rates of 62 to 73 percent in pregnancies when
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         was not taken and 9 to 36 percent of pregnancies in the same women when metformin was taken [
         <a href="#rid62">
          62-65
         </a>
         ].
        </p>
        <p>
         However, in a meta-analysis of 17 trials in women with PCOS taking
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         with or without
         <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">
          clomiphene
         </a>
         for ovulation induction, no effect of metformin was seen on the risk of pregnancy loss [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H167683613">
         <span class="h3">
          Gestational diabetes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Early studies also suggested that
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         therapy reduced the risk of gestational diabetes mellitus (GDM), but this was not confirmed in randomized trials.
        </p>
        <p>
         The incidence of GDM is severalfold higher in women with PCOS than in the general obstetric population [
         <a href="#rid65">
          65,67
         </a>
         ]. Two observational studies suggested that
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         use was associated with a lower risk of GDM, but this was not confirmed in a trial of 273 pregnancies among 257 women with PCOS who were randomly assigned to receive metformin (2000 mg/day) or placebo from the first trimester until delivery. There was no significant difference in prevalence of GDM between groups (metformin 17.6 percent versus placebo 16.9 percent) [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
         The treatment of established GDM is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6790.html" rel="external">
          "Gestational diabetes mellitus: Glucose management and maternal prognosis", section on 'Metformin'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h3">
          Other complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the same randomized trial of
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         versus placebo during pregnancy, no significant differences were seen in the prevalence of preeclampsia (7.4 versus 3.7 percent) or preterm delivery (3.7 versus 8.2 percent) or a composite outcome that included preeclampsia, preterm delivery, and GDM (overall rate of complications 25.9 and 24.4 percent for metformin and placebo, respectively) [
         <a href="#rid68">
          68
         </a>
         ]. Women taking metformin gained less weight than women in the placebo group (mean difference -2.2 kg).
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h3">
          Neonatal outcomes
         </span>
         <span class="headingEndMark">
          —
         </span>
         A meta-analysis of pregnancy outcome in 172 women after first-trimester exposure to
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         did not find an increased risk of major malformations when compared with control women (OR 0.50, 95% CI 0.15-1.60) [
         <a href="#rid69">
          69
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6790.html" rel="external">
          "Gestational diabetes mellitus: Glucose management and maternal prognosis", section on 'Metformin'
         </a>
         .)
        </p>
        <p>
         However, in utero exposure to
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         from the first trimester to birth among women with PCOS may be associated with excess weight of those children at 4 years of age [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3747510617">
         <span class="h2">
          Obesity
         </span>
         <span class="headingEndMark">
          —
         </span>
         At least 50 percent of women with PCOS are obese. For obese women with PCOS who need to lose weight, we suggest other weight loss medications or bariatric surgery rather than
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         . Some benefit is seen when metformin is combined with caloric restriction [
         <a href="#rid71">
          71-78
         </a>
         ], but metformin does not produce enough weight loss to qualify as a weight loss drug. We agree with the Endocrine Society 2013 guidelines and do not suggest metformin for women with PCOS and obesity unless they have impaired glucose tolerance and have failed lifestyle interventions. (See
         <a class="medical medical_review" href="/z/d/html/5376.html" rel="external">
          "Obesity in adults: Drug therapy"
         </a>
         and
         <a class="local">
          'Prevention of diabetes mellitus'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h1">
          ADDING METFORMIN TO ORAL CONTRACEPTIVES
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is currently inadequate evidence to recommend the routine addition of
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         to combined estrogen-progestin oral contraceptive (COC) therapy as it is still unclear whether this combination has important cosmetic or metabolic advantages over COC monotherapy.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one randomized clinical trial, 40 nonobese women with PCOS were treated with either a COC alone (ethinyl estradiol 35 mcg/day plus
         <a class="drug drug_general" data-topicid="9295" href="/z/d/drug information/9295.html" rel="external">
          cyproterone acetate
         </a>
         2 mg/day) or this COC plus
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         (500 mg three times daily) for four months [
         <a href="#rid79">
          79
         </a>
         ]. Combination therapy of the COC plus metformin resulted in the greatest reduction of the serum androstenedione level and the greatest increase in sex hormone-binding globulin (SHBG)  (
         <a class="graphic graphic_figure graphicRef56361" href="/z/d/graphic/56361.html" rel="external">
          figure 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Weight loss occurred only in the group taking
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         . Circulating androgen concentrations and Ferriman-Gallwey hirsutism scores decreased to a similar degree in both groups. Thus, the combination of metformin plus a COC may be useful when weight loss is desired but not when used for other indications.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a second trial, 30 women with PCOS were randomly assigned to receive a COC alone (ethinyl estradiol 35 mcg/day plus norgestimate 25 mcg/day) or in combination with
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         (1500 mg/day) for six months [
         <a href="#rid80">
          80
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although obese women were not specifically excluded, the population was relatively lean (mean body mass index [BMI]±standard deviation [SD] 22.1±3.1 and 24.7±4.9 kg/m
         <sup>
          2
         </sup>
         in the monotherapy and combined therapy groups, respectively). At six months, the only significant difference between the groups was a lower free androgen index in the combination compared with the monotherapy group. No differences were seen in lipids, insulin sensitivity (measured by euglycemic hyperinsulinemic clamp technique), SHBG, or testosterone. It is possible that results would be different in an obese population.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1318153421">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110097.html" rel="external">
          "Society guideline links: Polycystic ovary syndrome"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/110632.html" rel="external">
          "Society guideline links: Hirsutism"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15605.html" rel="external">
          "Patient education: Polycystic ovary syndrome (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/2163.html" rel="external">
          "Patient education: Polycystic ovary syndrome (PCOS) (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H27">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Use of
         </strong>
         <strong>
          metformin
         </strong>
         <strong>
          in PCOS
         </strong>
         –
         <strong>
         </strong>
         We no longer recommend the use of
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         as a first-line therapy for any indication in women with polycystic ovary syndrome (PCOS). However, it is still sometimes prescribed, and its use depends upon the individual patient's goals.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Oligomenorrhea/endometrial protection
         </strong>
         –
         <strong>
         </strong>
         For women with oligomenorrhea who need
         <strong>
          endometrial protection
         </strong>
         , we suggest combined estrogen-progestin oral contraceptives (COCs) as first-line therapy rather than
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         . For second-line therapy and for situations where COCs are contraindicated, we suggest continuous or cyclic progestin-only treatment, or a levonorgestrel-secreting intrauterine device (IUD) for endometrial protection. Metformin may also be used as second-line therapy (particularly in women with contraindications to pill use), but it has not been proven to be endometrial protective. When metformin is used, cyclic progestin therapy may be added for the first six months of metformin treatment until regular cycles are established. (See
         <a class="local">
          'Oligomenorrhea'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7421.html" rel="external">
          "Treatment of polycystic ovary syndrome in adults", section on 'Women pursuing pregnancy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hyperandrogenism
         </strong>
         –
         <strong>
         </strong>
         For management of hyperandrogenic symptoms alone, we suggest COCs as first-line therapy. We do not suggest one pill over another, as they are all effective. Other options are reviewed in detail separately. (See
         <a class="local">
          'Hirsutism'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7444.html" rel="external">
          "Management of hirsutism in premenopausal women"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ovulation induction
         </strong>
         –
         <strong>
         </strong>
         For women who desire
         <strong>
          pregnancy
         </strong>
         , we suggest weight loss. (We suggest this to all women with PCOS who are overweight or obese.) If they are unable to lose weight or modest weight loss does not restore ovulatory cycles, we suggest ovulation induction with
         <a class="drug drug_general" data-topicid="10064" href="/z/d/drug information/10064.html" rel="external">
          letrozole
         </a>
         . (See
         <a class="local">
          'Anovulatory infertility'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7421.html" rel="external">
          "Treatment of polycystic ovary syndrome in adults", section on 'Women pursuing pregnancy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pregnancy complications
         </strong>
         –
         <strong>
         </strong>
         We suggest against the use of
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         during pregnancy to prevent gestational diabetes mellitus (GDM)
         <strong>
         </strong>
         (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ).
         <strong>
         </strong>
         We also suggest against the routine use of metformin to prevent pregnancy loss in women with PCOS
         <strong>
         </strong>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
         <strong>
         </strong>
         (See
         <a class="local">
          'Prevention of pregnancy complications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management of metabolic issues
         </strong>
         –
         <strong>
         </strong>
         For women with PCOS who are found to have
         <strong>
          type 2 diabetes mellitus
         </strong>
         or impaired glucose tolerance (IGT), the management is the same as other non-PCOS patients with these disorders. (See
         <a class="local">
          'Prevention of diabetes mellitus'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          Metformin
         </a>
         is associated with an improvement in glucose levels and a reduction in blood pressure and low-density lipoprotein (LDL). In addition it may delay or prevent conversion of IGT to type 2 diabetes mellitus. (See
         <a class="local">
          'Prevention of diabetes mellitus'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Knochenhauer ES, Key TJ, Kahsar-Miller M, et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998; 83:3078.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999; 84:4006.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Asunción M, Calvo RM, San Millán JL, et al. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000; 85:2434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nestler JE. Metformin for the treatment of the polycystic ovary syndrome. N Engl J Med 2008; 358:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Metformin Therapy for the Management of Infertility in Women with Polycystic Ovary Syndrome: Scientific Impact Paper No. 13. BJOG 2017; 124:e306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferrannini E. The target of metformin in type 2 diabetes. N Engl J Med 2014; 371:1547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Madiraju AK, Erion DM, Rahimi Y, et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 2014; 510:542.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buse JB, DeFronzo RA, Rosenstock J, et al. The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies. Diabetes Care 2016; 39:198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Niafar M, Hai F, Porhomayon J, Nader ND. The role of metformin on vitamin B12 deficiency: a meta-analysis review. Intern Emerg Med 2015; 10:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glueck CJ, Wang P. Metformin before and during pregnancy and lactation in polycystic ovary syndrome. Expert Opin Drug Saf 2007; 6:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang C, Chang S, Poles J, Popov V. The Impact of Bariatric Surgery Compared to Metformin Therapy on Pregnancy Outcomes in Patients with Polycystic Ovarian Syndrome: a Systematic Review and Meta-analysis. J Gastrointest Surg 2021; 25:378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moghetti P, Castello R, Negri C, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000; 85:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Unlühizarci K, Keleştimur F, Bayram F, et al. The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1999; 51:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang PK, Hsu CY, Chen MJ, et al. The Efficacy of 24-Month Metformin for Improving Menses, Hormones, and Metabolic Profiles in Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2018; 103:890.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fleming R, Hopkinson ZE, Wallace AM, et al. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J Clin Endocrinol Metab 2002; 87:569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Velázquez E, Acosta A, Mendoza SG. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997; 90:392.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Genazzani AD, Battaglia C, Malavasi B, et al. Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. Fertil Steril 2004; 81:114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eisenhardt S, Schwarzmann N, Henschel V, et al. Early effects of metformin in women with polycystic ovary syndrome: a prospective randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2006; 91:946.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Essah PA, Apridonidze T, Iuorno MJ, Nestler JE. Effects of short-term and long-term metformin treatment on menstrual cyclicity in women with polycystic ovary syndrome. Fertil Steril 2006; 86:230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ibáñez L, Valls C, Ferrer A, et al. Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism. J Clin Endocrinol Metab 2001; 86:3595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carmina E, Lobo RA. Does metformin induce ovulation in normoandrogenic anovulatory women? Am J Obstet Gynecol 2004; 191:1580.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tang T, Lord JM, Norman RJ, et al. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev 2012; :CD003053.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morin-Papunen LC, Vauhkonen I, Koivunen RM, et al. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 2000; 85:3161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Costello M, Shrestha B, Eden J, et al. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst Rev 2007; :CD005552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nestler JE, Stovall D, Akhter N, et al. Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome. Fertil Steril 2002; 77:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tso LO, Costello MF, Albuquerque LE, et al. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst Rev 2009; :CD006105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palomba S, Falbo A, La Sala GB. Effects of metformin in women with polycystic ovary syndrome treated with gonadotrophins for in vitro fertilisation and intracytoplasmic sperm injection cycles: a systematic review and meta-analysis of randomised controlled trials. BJOG 2013; 120:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abdalmageed OS, Farghaly TA, Abdelaleem AA, et al. Impact of Metformin on IVF Outcomes in Overweight and Obese Women With Polycystic Ovary Syndrome: A Randomized Double-Blind Controlled Trial. Reprod Sci 2019; 26:1336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palomba S, Falbo A, Carrillo L, et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertil Steril 2011; 96:1384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al-Inany HG, Youssef MA, Ayeleke RO, et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev 2016; 4:CD001750.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Practice Committee of the American Society for Reproductive Medicine. Electronic address:
           <span class="__cf_email__" data-cfemail="125341405f527361607f3c7d6075">
            [email protected]
           </span>
           , Practice Committee of the American Society for Reproductive Medicine. Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline. Fertil Steril 2017; 108:426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lord JM, Flight IH, Norman RJ. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev 2003; :CD003053.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ehrmann DA, Barnes RB, Rosenfield RL, et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999; 22:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharma ST, Wickham EP 3rd, Nestler JE. Changes in glucose tolerance with metformin treatment in polycystic ovary syndrome: a retrospective analysis. Endocr Pract 2007; 13:373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ehrmann DA, Cavaghan MK, Imperial J, et al. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82:524.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998; 338:1876.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Velazquez EM, Mendoza S, Hamer T, et al. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994; 43:647.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996; 335:617.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dunaif A, Scott D, Finegood D, et al. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996; 81:3299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ehrmann DA, Schneider DJ, Sobel BE, et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82:2108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nestler JE, Jakubowicz DJ, Reamer P, et al. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 1999; 340:1314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ibáñez L, Valls C, Ferrer A, et al. Additive effects of insulin-sensitizing and anti-androgen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation. J Clin Endocrinol Metab 2002; 87:2870.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ibáñez L, Valls C, Potau N, et al. Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. J Clin Endocrinol Metab 2000; 85:3526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasquali R, Antenucci D, Casimirri F, et al. Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J Clin Endocrinol Metab 1989; 68:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril 2000; 73:1149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelly CJ, Gordon D. The effect of metformin on hirsutism in polycystic ovary syndrome. Eur J Endocrinol 2002; 147:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harborne L, Fleming R, Lyall H, et al. Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88:4116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin KA, Anderson RR, Chang RJ, et al. Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2018; 103:1233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glueck CJ, Wang P, Fontaine R, et al. Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. Metabolism 1999; 48:511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           George SS, George K, Irwin C, et al. Sequential treatment of metformin and clomiphene citrate in clomiphene-resistant women with polycystic ovary syndrome: a randomized, controlled trial. Hum Reprod 2003; 18:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kocak M, Caliskan E, Simsir C, Haberal A. Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome. Fertil Steril 2002; 77:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vandermolen DT, Ratts VS, Evans WS, et al. Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil Steril 2001; 75:310.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morin-Papunen L, Rantala AS, Unkila-Kallio L, et al. Metformin improves pregnancy and live-birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double-blind, placebo-controlled randomized trial. J Clin Endocrinol Metab 2012; 97:1492.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Legro RS, Barnhart HX, Schlaff WD, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 2007; 356:551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moll E, Bossuyt PM, Korevaar JC, et al. Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ 2006; 332:1485.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palomba S, Orio F Jr, Falbo A, et al. Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90:4068.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zain MM, Jamaluddin R, Ibrahim A, Norman RJ. Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertil Steril 2009; 91:514.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson NP, Stewart AW, Falkiner J, et al. PCOSMIC: a multi-centre randomized trial in women with PolyCystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene. Hum Reprod 2010; 25:1675.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siebert TI, Viola MI, Steyn DW, Kruger TF. Is metformin indicated as primary ovulation induction agent in women with PCOS? A systematic review and meta-analysis. Gynecol Obstet Invest 2012; 73:304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Misso ML, Costello MF, Garrubba M, et al. Metformin versus clomiphene citrate for infertility in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2013; 19:2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril 2008; 89:505.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glueck CJ, Wang P, Goldenberg N, Sieve-Smith L. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod 2002; 17:2858.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jakubowicz DJ, Iuorno MJ, Jakubowicz S, et al. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 2002; 87:524.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glueck CJ, Phillips H, Cameron D, et al. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil Steril 2001; 75:46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thatcher SS, Jackson EM. Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin. Fertil Steril 2006; 85:1002.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palomba S, Falbo A, Orio F Jr, Zullo F. Effect of preconceptional metformin on abortion risk in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Fertil Steril 2009; 92:1646.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mikola M, Hiilesmaa V, Halttunen M, et al. Obstetric outcome in women with polycystic ovarian syndrome. Hum Reprod 2001; 16:226.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vanky E, Stridsklev S, Heimstad R, et al. Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study. J Clin Endocrinol Metab 2010; 95:E448.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gilbert C, Valois M, Koren G. Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis. Fertil Steril 2006; 86:658.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanem LGE, Stridsklev S, Júlíusson PB, et al. Metformin Use in PCOS Pregnancies Increases the Risk of Offspring Overweight at 4 Years of Age: Follow-Up of Two RCTs. J Clin Endocrinol Metab 2018; 103:1612.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasquali R, Gambineri A, Biscotti D, et al. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 2000; 85:2767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kay JP, Alemzadeh R, Langley G, et al. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism 2001; 50:1457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 2001; 107:E55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harborne LR, Sattar N, Norman JE, Fleming R. Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. J Clin Endocrinol Metab 2005; 90:4593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moran LJ, Pasquali R, Teede HJ, et al. Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Fertil Steril 2009; 92:1966.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yki-Järvinen H, Nikkilä K, Mäkimattila S. Metformin prevents weight gain by reducing dietary intake during insulin therapy in patients with type 2 diabetes mellitus. Drugs 1999; 58 Suppl 1:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haupt E, Knick B, Koschinsky T, et al. Oral antidiabetic combination therapy with sulphonylureas and metformin. Diabete Metab 1991; 17:224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stumvoll M, Nurjhan N, Perriello G, et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333:550.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elter K, Imir G, Durmusoglu F. Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Hum Reprod 2002; 17:1729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cibula D, Fanta M, Vrbikova J, et al. The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Hum Reprod 2005; 20:180.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7411 Version 25.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9745406" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10566641" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10902790" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18172174" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Metformin for the treatment of the polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28834093" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Metformin Therapy for the Management of Infertility in Women with Polycystic Ovary Syndrome: Scientific Impact Paper No. 13.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25317875" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : The target of metformin in type 2 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24847880" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26285584" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25502588" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : The role of metformin on vitamin B12 deficiency: a meta-analysis review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17367265" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Metformin before and during pregnancy and lactation in polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33483916" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : The Impact of Bariatric Surgery Compared to Metformin Therapy on Pregnancy Outcomes in Patients with Polycystic Ovarian Syndrome: a Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10634377" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10468995" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29325133" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : The Efficacy of 24-Month Metformin for Improving Menses, Hormones, and Metabolic Profiles in Polycystic Ovary Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11836287" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9277650" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Menstrual cyclicity after metformin therapy in polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14711553" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16352680" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Early effects of metformin in women with polycystic ovary syndrome: a prospective randomized, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16716324" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Effects of short-term and long-term metformin treatment on menstrual cyclicity in women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11502783" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15547527" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Does metformin induce ovulation in normoandrogenic anovulatory women?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22592687" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10999803" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17253562" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11821072" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19370625" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23194199" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Effects of metformin in women with polycystic ovary syndrome treated with gonadotrophins for in vitro fertilisation and intracytoplasmic sperm injection cycles: a systematic review and meta-analysis of randomised controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29576001" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Impact of Metformin on IVF Outcomes in Overweight and Obese Women With Polycystic Ovary Syndrome: A Randomized Double-Blind Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21982727" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27126581" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Gonadotrophin-releasing hormone antagonists for assisted reproductive technology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28865539" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12917943" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10333916" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17669713" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Changes in glucose tolerance with metformin treatment in polycystic ovary syndrome: a retrospective analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9024248" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9637806" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8177055" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8687515" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8784087" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9215280" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10219066" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12050266" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Additive effects of insulin-sensitizing and anti-androgen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11061495" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2642485" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10856473" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12153743" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : The effect of metformin on hirsutism in polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12970273" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29522147" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10206447" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12571165" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Sequential treatment of metformin and clomiphene citrate in clomiphene-resistant women with polycystic ovary syndrome: a randomized, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11779598" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11172832" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22419702" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Metformin improves pregnancy and live-birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double-blind, placebo-controlled randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17287476" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16769748" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15840746" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18321486" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20435692" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : PCOSMIC: a multi-centre randomized trial in women with PolyCystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22516925" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Is metformin indicated as primary ovulation induction agent in women with PCOS? A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22956412" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Metformin versus clomiphene citrate for infertility in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18243179" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Consensus on infertility treatment related to polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12407039" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11836280" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Effects of metformin on early pregnancy loss in the polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11163815" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16580387" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18937939" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Effect of preconceptional metformin on abortion risk in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11157811" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Obstetric outcome in women with polycystic ovarian syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20926533" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16879826" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29490031" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Metformin Use in PCOS Pregnancies Increases the Risk of Offspring Overweight at 4 Years of Age: Follow-Up of Two RCTs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10946879" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11735093" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Beneficial effects of metformin in normoglycemic morbidly obese adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11335776" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15886247" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19062007" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10576526" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Metformin prevents weight gain by reducing dietary intake during insulin therapy in patients with type 2 diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1936481" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Oral antidiabetic combination therapy with sulphonylureas and metformin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7623903" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Metabolic effects of metformin in non-insulin-dependent diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12093831" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15576394" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
